IM Cannabis Corp. key statistics and ratios
In fiscal 2025, IM Cannabis Corp. had an operating margin of -21.2% and a current ratio of 0.67. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross margin | 43.3% | 65.9% | 18.6% | 16.9% | 20.2% | 15.6% | 17.7% |
| Operating margin | −113.2% | −51.9% | −67.6% | −56.7% | −26.2% | −18.9% | −21.2% |
| Net margin | −80.4% | −180.6% | −52.2% | −347.6% | −19.5% | −19.6% | −20.7% |
| Free-cash-flow margin | −82.7% | −66.3% | −114.4% | −26.1% | −17.7% | −2.3% | 8.6% |
| Return on equity | −28.9% | −154.4% | −17.1% | −166.8% | −50.8% | −105.9% | — |
| Return on assets | −23.1% | −79.7% | −11.1% | −107.7% | −17.2% | −24.1% | −32.2% |
| Asset turnover | 0.29 | 0.44 | 0.21 | 0.31 | 0.88 | 1.23 | 1.56 |
| Current ratio | 9.31 | 4.33 | 1.58 | 0.97 | 0.74 | 0.67 | 0.67 |
| Debt to equity | 0.0% | 0.0% | 6.3% | 42.6% | 89.2% | 306.6% | — |
| Interest cover (operating income ÷ interest) | — | — | — | n/m | n/m | n/m | n/m |
| R&D as % of revenue | 2.6% | 0.9% | — | — | — | — | — |
| Capital spending as % of revenue | 17.0% | 16.5% | 13.4% | 2.9% | 1.2% | 0.3% | 0.0% |
Financial health
- Short-term assets cover short-term liabilities $17m of assets due within a year against $25m of liabilities due within a year.
- Short-term assets cover long-term liabilities $17m short-term assets against $980,893 of longer-dated liabilities.
- More cash than debt $2m of cash against $12m of debt.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt $3m of operating cash flow against $12m of debt.
- Operating profit covers interest at least five times over Operating income of −$8m against $29,353 of interest.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Compare with peers
- Cumberland Pharmaceuticals Inc statistics
- BGM Group Ltd. statistics
- Sunshine Biopharma Inc. statistics
- Biofrontera Inc. statistics
- Scilex Holding Co statistics
Head to head: CPIX vs IMCCBGM vs IMCCIMCC vs SBFMBFRI vs IMCC
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies